Previous 10 | Next 10 |
While the S&P 500 index added ~1.8% gain over the week, its healthcare constituents underperformed with a ~0.8% rise yet, recording their first weekly gain in more than a month. Dragged down by pharma stocks, the sector became the second-worst performer in the index for ano...
Gainers: Nutriband (NTRBW) +97%. Nutriband (OTCQB:NTRB) +41%. R. R. Donnelley & Sons (NYSE:RRD) +38%. Tiptree (NASDAQ:TIPT) +27%. Inhibrx (NASDAQ:INBX) +24%. Weatherford (NASDAQ:WFRD) +20%. NRx Pharmaceuticals (NASDAQ:NRXP) +19%. Xiaobai Maimai (NASDAQ:HX) +19%. Ocugen (NASDAQ:OCGN) +16%....
Protagonist Therapeutics to Present at the Jefferies Next Generation IBD Therapeutics Summit PR Newswire NEWARK, Calif. , Oct. 12, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V....
FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Protagonist Therapeutics, Inc. Announces Removal of FDA Clinical Hold on the Rusfertide Clinical Development Program” Protagonist Therapeutics, Inc. (NASDAQ: PTGX) ...
4 Trending Biotech Stocks To Watch Amid AstraZeneca’s News While investors eagerly await the beginning of the third-quarter earnings season, biotech stocks continue to gain traction. For the most part, this area of the stock market today has plenty to offer investors now....
Gainers: Protagonist (NASDAQ:PTGX) +86%. Adamas (NASDAQ:ADMS) +75%. Flexion (NASDAQ:FLXN) +63%. Progenity (NASDAQ:PROG) +35%. Gaotu Techedu (NYSE:GOTU) +23%. U.S. Well Services (NASDAQ:USWS) +22%. Blue Apron (NYSE:APRN) +19%. EZFill (NASDAQ:EZFL) +18%. Ocular (NASDAQ:OCUL) +17%. Willamette Va...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Daqo New Energy (NYSE: DQ ) stock is rising higher on Monday as one analyst calls it out as a top pick in the polysilicon category. Source: Shutterstock Jefferies analyst Johnson Wan is behind today’s n...
Shares of Protagonist Therapeutics Inc ( NASDAQ: PTGX ) nearly doubled on Monday as the U.S. FDA said it could resume the clinical trials for Rusfertide – an investigational, injectable hepcidin mimetic. The U.S. FDA had paused the clinical studies last month The drug...
Gainers: Protagonist Therapeutics (NASDAQ:PTGX) +82%, Adamas Pharmaceuticals (NASDAQ:ADMS) +74%, Flexion Therapeutics (NASDAQ:FLXN) +62%, Evelo Biosciences (NASDAQ:EVLO) +16%, Progenity (NASDAQ:PROG) +16%. Losers: Voyager Therapeutics (NASDAQ:VYGR)...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Protagonist Therapeutics (NASDAQ: PTGX ) stock is rocketing higher on Monday thanks to an update from the U.S. Food and Drug Administration (FDA) concerning rusfertide clinical studies. Source: JHVEPhoto / Shutter...
News, Short Squeeze, Breakout and More Instantly...
Protagonist Therapeutics Inc. Company Name:
PTGX Stock Symbol:
NASDAQ Market:
Protagonist Therapeutics Inc. Website:
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal Scientific Reports , a Nature publication and the 5th most-cited journal in the world, acc...
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal Scientific Reports , a Nature publication and the 5th most-cited journal in the world, acc...
Dr. Yeilding joins Protagonist from Janssen Pharmaceutical Companies of Johnson & Johnson, where he held leadership roles in the immunology therapeutic area, bringing extensive experience in R&D and commercialization of novel therapeutics in the I&I space NEWARK, CA / ACCESSWIRE /...